Pharmacological characterization of actin-binding (-)-doliculide

Area of Science:

• Natural product chemistry
• Cell biology
• Cancer research

Background:

• Natural compounds are a rich source of anti-cancer drugs, with many targeting microtubules.
• The actin cytoskeleton is crucial for cell functions, but actin-targeting compounds are less explored for cancer therapy.
• Doliculide, a marine-derived natural product, binds to actin, but its anti-cancer properties are poorly understood.

Purpose of the Study:

• To characterize the effects of doliculide on breast cancer cell lines.
• To investigate doliculide's impact on the actin cytoskeleton and cellular functions.
• To evaluate doliculide as a potential therapeutic lead for breast cancer.

Main Methods:

• Fluorescence-recovery-after-photobleaching (FRAP) to assess early actin cytoskeleton dynamics.
• Rhodamine-phalloidin staining for long-term actin cytoskeleton effects.
• Cell proliferation assays, migration assays, and apoptosis assays.

Main Results:

• Doliculide disrupts the actin cytoskeleton in MCF7 and MDA-MB-231 breast cancer cells.
• Doliculide treatment inhibits cell proliferation and impairs cell migration.
• Doliculide induces apoptosis in both tested breast cancer cell lines.

Conclusions:

• Doliculide effectively targets the actin cytoskeleton in breast cancer cells.
• Doliculide exhibits anti-proliferative, anti-migratory, and pro-apoptotic effects.
• Doliculide represents a promising lead structure for developing novel actin-targeting anti-cancer therapeutics.